A review of psychophysiological stressors on pharmacokinetics.

Defence Research and Development Canada-Toronto, 1133 Sheppard Avenue West, P.O. Box 2000, Toronto, Ontario, Canada M3M 3B9.
The Journal of Clinical Pharmacology (Impact Factor: 2.47). 11/2011; 51(11):1499-518. DOI: 10.1177/0091270010393344
Source: PubMed

ABSTRACT We conducted a comprehensive literature review on the effects of psychophysiological stressors on the pharmacokinetics of drugs commonly used by the Canadian Forces. These stressors may change the physiological status of an individual and subsequently may alter the drug's pharmacokinetics. The effects of isolated physical activities on pharmacokinetics have been well documented. However, the findings are inconsistent due to variations in the intensity and duration of the activity, and the routes and timing of drug administration. The effects of other environmental stressors, such as temperature extremes, hypobaric, hyperbaric, hyperoxic conditions, and the effects of multiple stressors are less well known. There are limited studies describing the effects of psychological stressors on drug pharmacokinetics. Further studies are necessary to understand the clinical implications of pharmacokinetic changes. We also discussed the advantage of using a physiologically based pharmacokinetic model to predict the effects of a single or multiple stressors.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Research on the specific effects of sex and gender on pharmacokinetics and pharmacodynamics, as well as safety profile tolerability and drug efficacy, of medications remain meager because female animals and women have only recently been included in the pharmacological domain. To date, the influence of sex and gender on access to care and emotional factors, including patients and care provider dyads, the placebo effect, adherence, and safety profiles, are discussed. Furthermore, differences in drug responses, mainly for antidiabetic drugs, have been described. However, further studies are needed to explore the impact of sex and gender on reaching the most appropriate and tailored prescription for each patient, regardless of sex and gender.
    Expert Review of Clinical Pharmacology 05/2014; DOI:10.1586/17512433.2014.922866
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Most drugs are metabolized in the liver by cytochromes P450 (CYPs). Stress can modify CYP-catalyzed drug metabolism and subsequently, the pharmacokinetic profile of a drug. Current evidence demonstrates a gene-, stress- and species-specific interference in stress-mediated regulation of genes encoding the major drug-metabolizing CYP isozymes. Stress-induced up-regulation of CYPs that metabolize the majority of prescribed drugs can result in their increased metabolism and consequently, in failure of pharmacotherapy. In contrast, stress-induced down-regulation of CYP isozymes, including CYP2E1 and CYP2B1/2, potentially reduces metabolism of several toxicants and specific drugs-substrates resulting in increased levels and altered toxicity. The primary stress effectors, the adrenergic receptor-linked pathways and glucocorticoids, play primary and distinct roles in stress-mediated regulation of CYPs. Evidence demonstrates that stress regulates major drug metabolizing CYP isozymes, suggesting that stress should be considered to ensure pharmacotherapy efficacy and minimize drug toxicity. A detailed understanding of the molecular events underlying the stress-dependent regulation of drug metabolizing CYPs is crucial both for the design of new drugs and for physiology-based pharmacokinetic and pharmacodynamic modeling.
    Neuroscience & Biobehavioral Reviews 05/2014; 45. DOI:10.1016/j.neubiorev.2014.05.011 · 10.28 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Drug metabolism is affected by many social-psychological factors including mood disorder. Organ transplantation recipients usually suffer from depression. The study aims to explore whether depression disorder alters immunosuppresant Tacrolimus (TAC) pharmacokinetic process in depression model rats. Eighteen female Sprague-Dawley (SD) rats were randomized into model group and control group. Depression model rats were built with Chronic Unpredicted Mild Stresses (CUMS) for 8 weeks. After 8 weeks model establishment, all rats in both groups were given TAC (1.5 mg kg(-1)) i.g. Blood samples were collected at various time points. TAC concentration was assayed by high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). TAO pharmacokinetic parameters were processed with DAS software. Compared to those in control group, there was significant decrease in C-max and AUC in depression model group (p<0.05), from 0.87+/-0.06 to 0.79+/-0.05 mu g mL(-1)(C-max) and from 2.35+/-0.23 to 2.14+/-0.08 mu g mL(-1).h (AUC), respectively. The results indicated that depression disorder alter TAC pharmacokinetic process which might be induced by enhancing the drug metabolism.
    International Journal of Pharmacology 04/2013; 9(4):265-270. DOI:10.3923/ijp.2013.265.270 · 0.98 Impact Factor


Available from
Jan 1, 2015